Skip to content
Austin Top 50
Author:
EeroQ
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment – with Superior Oral Administration and Escape Resistance Features Over Antibodies
June 8, 2026
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
May 26, 2026
Ebola Global Health Emergency Needs a Broad-Spectrum Drug – NV-387 is a Strong Potential Candidate, Says NanoViricides
May 18, 2026
NanoViricides, Inc. Has Filed its Quarterly Report – NV-387 Advancing for Phase II
May 15, 2026
EeroQ and Conductor Demonstrate Autonomous Future of Quantum Computing Labs using NVIDIA Ising
April 14, 2026
←
Previous Page
1
2